Investment Rating - The report does not provide a specific investment rating for the industry or companies mentioned [1]. Core Insights - The report highlights several new stock listings and trading activities scheduled for November 18, 2025, including companies such as Jingchuang Electric (12.10), Beikang Testing (6.70), and Nanguang Digital (5.69) [1]. - It also mentions various corporate actions such as tender offers, cash options, and acquisition requests, indicating active market movements [1]. Summary by Relevant Sections - **New Stock Listings**: Companies like Jingchuang Electric, Beikang Testing, and Nanguang Digital are set to debut on the market with respective prices of 12.10, 6.70, and 5.69 [1]. - **Corporate Actions**: The report details several corporate actions including a tender offer for Tianpu Co. (605255) from November 20 to December 19, 2025, and cash options for Hangqi Wheel B (200771) from November 19 to November 25, 2025 [1]. - **Market Alerts**: It lists companies experiencing significant fluctuations, such as Moen Electric (002451) and Huasheng Lithium Battery (688353), indicating potential investment risks and opportunities [1].

Market Overview - The Chinese medicine sector experienced a decline of 1.1% on November 18, with Te Yi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Te Yi Pharmaceutical (002728) saw a significant drop of 10.02%, closing at 12.75 [2] - Other notable declines included Zhongsheng Pharmaceutical (002317) down 9.99% and Jiaying Pharmaceutical (002198) down 9.96% [2] - The trading volume for Te Yi Pharmaceutical was 978,300 shares, indicating high activity despite the price drop [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 1.771 billion yuan from institutional investors, while retail investors saw a net inflow of 1.701 billion yuan [2][3] - The data indicates that while institutional investors are pulling back, retail investors are actively buying into the sector [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 14.04 million yuan from institutional investors, while it faced a net outflow of 21.57 million yuan from speculative funds [3] - Lingrui Pharmaceutical (600285) also saw a net inflow of 9.86 million yuan from institutional investors, but faced outflows from both speculative and retail investors [3]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 嘉应制药(002198.SZ)公告称，公司股票交易价格连续两个交易日累计偏离22.47%，属于股票交易异常 波动情况。经核实，公司前期披露信息无更正或补充，近期经营正常，内外部环境无重大变化，无未公 开重大信息影响股价，公司无控股股东和实际控制人，不存在应披露而未披露的重大事项或筹划阶段的 重大事项。公司5%以上股东在股票异常波动期间未买卖公司股票。此外，公司因涉嫌信息披露违法违 规被证监会立案调查，目前尚未收到最终决定。 ...

本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动情况 广东嘉应制药股份有限公司（以下简称"公司"）股票（证券简称：嘉应制 药，证券代码：002198）交易价格连续2个交易日内（2025年11月14日、2025年 11月17日）收盘价格累计偏离22.47%。根据《深圳证券交易所股票交易规则》相 关规定，属于股票交易异常波动的情况。 证券代码：002198 证券简称：嘉应制药 公告编号：2025-061 广东嘉应制药股份有限公司 关于股票交易异常波动的公告 针对公司股票异常波动情况，根据相关规定的要求，公司对有关事项进行了 核查，并发函询问了公司5%以上机构股东东方证券股份有限公司、养天和大药 房股份有限公司，现就相关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、近期公司经营情况正常，内外部经营环境未发生重大变化； 3、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 4、公司目前无控股股东和实际控制人，公司不存在应披露而未披露的重大 事项，亦不存在处于筹划阶段的重大事项； 二 ...

Market Overview - The Chinese traditional medicine sector experienced a decline of 1.47% on November 17, with Wanbangde leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Jiaying Pharmaceutical (002198) with a closing price of 8.43, up 10.05% and a trading volume of 390,200 shares [1] - Weikang Pharmaceutical (300878) closed at 29.62, up 6.85% with a trading volume of 97,100 shares [1] - Significant losers included: - Wanbangde (002082) closed at 13.61, down 6.91% with a trading volume of 186,000 shares [2] - Teyi Pharmaceutical (002728) closed at 14.17, down 6.84% with a trading volume of 1,277,300 shares [2] Capital Flow - The traditional medicine sector saw a net outflow of 1.639 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.444 billion yuan [2][3] - The main stocks with significant capital inflow included: - Jiaying Pharmaceutical with a net inflow of 62.818 million yuan, accounting for 19.12% of its trading volume [3] - Huasheng Technology (000790) with a net inflow of 20.121 million yuan, representing 11.37% of its trading volume [3]

转自：证券时报 人民财讯11月17日电，嘉应制药(002198)11月17日发布股票交易异常波动的公告，近期公司经营情况正 常，内外部经营环境未发生重大变化，公司目前无控股股东和实际控制人，公司不存在应披露而未披露 的重大事项，亦不存在处于筹划阶段的重大事项。 ...

证券代码：002198 证券简称：嘉应制药 公告编号：2025-061 二、公司关注并核实相关情况 针对公司股票异常波动情况，根据相关规定的要求，公司对有关事项进行了 核查，现就相关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、近期公司经营情况正常，内外部经营环境未发生重大变化； 3、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 广东嘉应制药股份有限公司 关于股票交易异常波动的公告 本公司及全体董事会成员保证本公告内容的真实、准确和完整，不存在虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动情况 广东嘉应制药股份有限公司（以下简称"公司"）股票（证券简称：嘉应制 药，证券代码：002198）交易价格连续3个交易日内（2025年11月13日、2025年 11月14日、2025年11月17日）收盘价格涨幅偏离值累计超过20%。根据《深圳证 券交易所股票交易规则》相关规定，属于股票交易异常波动的情况。 敬请广大投资者理性投资，注意风险。 特此公告。 广东嘉应制药股份有限公司董事会 4、公司目前无控股股东和实际控制人，公司不存在应披露而未 ...

Core Viewpoint - The stock price of Jiaying Pharmaceutical has experienced a cumulative increase of over 20% in the closing prices over three consecutive trading days (November 13, 14, and 17, 2025) [1] Group 1: Stock Performance - The company's stock price has shown significant volatility, with a cumulative increase exceeding 20% over three trading days [1] - The company has confirmed that there are no corrections or supplements needed for previously disclosed information [1] Group 2: Operational Status - The company's operational situation remains normal, with no significant changes in the internal and external business environment [1] - There have been no recent media reports that could have significantly impacted the company's stock price [1] Group 3: Corporate Governance - The company currently has no controlling shareholder or actual controller [1] - There are no undisclosed significant matters that the company is obligated to disclose, nor are there any significant matters in the planning stage [1]

一、买卖嘉应制药002198股票的对账单原件 （1）对账单原件需要加盖证券公司营业部印章； 登录新浪财经APP 搜索【信披】查看更多考评等级 2025年5月28日晚间，广东嘉应制药（维权）股份有限公司（证券简称：嘉应制药，证券代码： 002198）发布《关于收到中国证券监督管理委员会立案告知书的公告》。公告显示：公司于近日收到中 国证券监督管理委员会《立案告知书》。根据《立案告知书》，因涉嫌信息披露违法违规，根据《中华 人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定立案。 经查，嘉应制药涉嫌的违法违规事实主要包括：未及时披露关联交易及关联方非经营性资金占用。2024 年第四季度，公司与养天和大药房股份有限公司等发生多笔关联交易，涉及金额1039.94万元，未及时 履行审议程序和信息披露义务，直至2025年4月才进行补充披露。此外，2024年9月至2025年1月期间， 关联方湖南药聚能医药有限公司以"月初转出、月末转回"的方式非经营性占用嘉应制药资金，累计金额 达到约2.35亿元。 上海百悦律师事务所牛彬律师表示，嘉应制药遭证监会立案，投资者或可索赔。 初步索赔范围：2024-10-0 ...

Core Insights - The traditional Chinese medicine sector experienced a slight increase of 0.52% on November 14, with Jia Ying Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Jia Ying Pharmaceutical (002198) closed at 7.66, up 10.06% with a trading volume of 275,500 shares and a transaction value of 203 million yuan [1] - Zhongsheng Pharmaceutical (002317) closed at 26.00, up 9.98% with a trading volume of 791,200 shares and a transaction value of 2.03 billion yuan [1] - Te Yi Pharmaceutical (002728) closed at 15.21, up 9.98% with a trading volume of 1,662,000 shares and a transaction value of 2.44 billion yuan [1] - Other notable performers include Fangsheng Pharmaceutical (603998) with a 4.92% increase and Kangyuan Pharmaceutical (600557) with a 4.53% increase [1] Capital Flow - The traditional Chinese medicine sector saw a net inflow of 541 million yuan from institutional investors, while retail investors experienced a net outflow of 17.84 million yuan [2] - Major stocks like Zhongsheng Pharmaceutical and Te Yi Pharmaceutical had significant net inflows from institutional investors, indicating strong interest [3] - Conversely, retail investors showed a tendency to withdraw from several stocks, including Jia Ying Pharmaceutical and Kangyuan Pharmaceutical, reflecting a cautious sentiment [3]